MainOPDP tracks the incoming volume of prescription drug promotional pieces that it receives each month. Companies are required to submit copies of the pieces they develop to promote their prescription drugs on Form FDA-2253 at the time these pieces are first publicly used (these submissions are referred to as “2253” submissions). OPDP monitors incoming 2253 submissions to examine trends in prescription drug promotion both by promotion target (e.g., consumers versus healthcare professionals) and by channel (e.g., print, broadcast, internet). For example, in recent years OPDP has seen a large increase in the volume of 2253 submissions that are internet-based, and this is one of the trends it is tracking under Measure B. This measure also provides a surrogate measure of OPDP’s potential workload by capturing the total amount of prescription drug promotion that is developed and disseminated during given periods of time; as such, it is useful to monitor to help ensure the efficient allocation of review resources within OPDP. <br>These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research. </b> Number

FY 2010 Total: 81,978

Oct 20097,523Nov 20097,663Dec 20096,433Jan 20105,984Feb 20105,717Mar 20107,906Apr 20106,828May 20106,838Jun 20107,412Jul 20106,375Aug 20106,431Sep 20106,868

FY 2011 Total: 81,142

Oct 20106,294Nov 20106,637Dec 20106,089Jan 20116,185Feb 20115,796Mar 20117,425Apr 20116,919May 20117,914Jun 20117,726Jul 20116,299Aug 20116,971Sep 20116,887

FY 2012 YTD: 21,532

Oct 20117,819Nov 20117,358Dec 20116,355Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012http://www.fda.gov/AboutFDA/Transparency/track/ucm206444.htmFDA-TRACK CDER DashboardSubTotal 2253 pieces (Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use) receivedPercent0100

Oct 200971Nov 200978Dec 200972Jan 201069Feb 201074Mar 201074Apr 201077May 201078Jun 201080Jul 201073Aug 201071Sep 2010710100

Oct 201073Nov 201076Dec 201069Jan 201170Feb 201174Mar 201182Apr 201176May 201176Jun 201174Jul 201168Aug 201167Sep 201169100

Oct 201166Nov 201170Dec 201165Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012SubTotal 2253 pieces (Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use) receivedPercent0100

Oct 200929Nov 200922Dec 200928Jan 201031Feb 201026Mar 201026Apr 201023May 201022Jun 201020Jul 201027Aug 201029Sep 2010290100

Oct 201027Nov 201024Dec 201031Jan 201130Feb 201126Mar 201118Apr 201124May 201124Jun 201126Jul 201132Aug 201133Sep 201131100

Oct 201134Nov 201130Dec 201135Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012SubTotal 2253 pieces (Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use) receivedPercent0100

Oct 200917Nov 200918Dec 200926Jan 201020Feb 201020Mar 201020Apr 201020May 201020Jun 201023Jul 201021Aug 201024Sep 2010200100

Oct 201021Nov 201023Dec 201028Jan 201126Feb 201122Mar 201122Apr 201121May 201120Jun 201122Jul 201124Aug 201126Sep 201126100

Oct 201123Nov 201123Dec 201127Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012SubTotal 2253 pieces (Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use) receivedPercent0100

Oct 200983Nov 200982Dec 200974Jan 201080Feb 201080Mar 201080Apr 201080May 201080Jun 201077Jul 201079Aug 201076Sep 2010800100

Oct 201079Nov 201077Dec 201072Jan 201174Feb 201178Mar 201178Apr 201179May 201180Jun 201178Jul 201176Aug 201174Sep 201174100

Oct 201177Nov 201177Dec 201173Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012਍††਍਍਍਍਍਍਍